Takamizawa H, Kobayashi O, Katoh T, Shirotake S, Endou N, Ishige H
Nihon Sanka Fujinka Gakkai Zasshi. 1982 Oct;34(10):1729-35.
We studied the remission and the recurrent of trophoblastic disease treated in our clinic, during 1973 to 1980. 1) The remission and recurrent rates of 168 cases were 91.1% (153/168) and 5.2% (8/153) respectively. In these percentages, high risk was 65.9% (29/44) and 20.7% (6/29), low risk was 100% (124/124) and 1.6% (2/124), choriocarcinoma was 58.3% (21/36) and 28.6% (6/21), invasive mole was 100% (44/44) and 0, and undetermined was 100% (88/88) and 2.3% (2/88). 2) The interval to recurrence: 5 cases appeared under a year, 3 cases did over a year. And remission rate of recurrent case was (4/8), high risk was (2/6), and low risk was (2/2). 3) HCG-beta titers when U-hCG decreased under the LH levels was higher until 3 months in the recurrent case of high risk than that unrecurrent, while we did not recognize any differences after 3 months. Therefore criteria of remission in high risk would occurred on continuous LH levels of U-hCG for 3 months. 4) High risk has been treated by 3 courses of additional chemotherapy, but that when hCG-beta titer over 1.0ng/ml require more chemotherapy.
我们研究了1973年至1980年期间在我们诊所接受治疗的滋养细胞疾病的缓解和复发情况。1）168例患者的缓解率和复发率分别为91.1%（153/168）和5.2%（8/153）。在这些百分比中，高危患者为65.9%（29/44）和20.7%（6/29），低危患者为100%（124/124）和1.6%（2/124），绒毛膜癌为58.3%（21/36）和28.6%（6/21），侵蚀性葡萄胎为100%（44/44）和0，未明确类型为100%（88/88）和2.3%（2/88）。2）复发间隔：5例在1年内复发，3例在1年后复发。复发病例的缓解率为（4/8），高危患者为（2/6），低危患者为（2/2）。3）在高危复发病例中，当尿人绒毛膜促性腺激素（U-hCG）降至促黄体生成素（LH）水平以下时，其β亚单位（HCG-β）滴度在3个月内一直高于未复发病例，而3个月后未发现任何差异。因此，高危患者的缓解标准应为U-hCG持续3个月处于LH水平。4）高危患者接受了3个疗程的追加化疗，但当HCG-β滴度超过1.0ng/ml时需要更多化疗。
